The Rheumatoid Arthritis Community is Swelling with Anticipation as its Research Pipeline Begins to Burst

GlobalData, June 2012, Pages: 4

The Rheumatoid Arthritis Community is Swelling with Anticipation as its Research Pipeline Begins to Burst

Summary

GlobalData's analysis alert "The Rheumatoid Arthritis Community is Swelling with Anticipation as its Research Pipeline Begins to Burst”, analyzes the current pipeline for rheumatoid arthritis drug therapeutics. In addition to the anticipated upcoming approval of Pfizer’s tofacitinib, the pipeline has other entities waiting in the wings. Tofacitinib conquers the troublesome formulation issue as it is administered in oral doses, but other compounds are in development in oral form as well. Tofacitinib also tackles the JAK pathway which current RA therapies do not target, and there are other kinase inhibitors in the development pipeline. Also, there is the possibility of a DNA vaccine which will minimize early symptoms of RA. Finally, we look at a new potential pathway to target in order to inhibit inflammation and joint destruction for people suffering from RA.

Scope

- Details of select upcoming RA therapies with clinical trial results.
- Discussion of a possible new pathway which may be involved with the promotion of RA.

Reasons to buy

- Important details of the select RA therapies are discussed along with ACR response results from clinical trials.
- Stay informed about the RA pipeline, which has an abundance of activity, and some unmet needs will be answered in the near future.

1
1

2 Introduction
2.1 Pfizer’s tofacitinib, a JAK 3 Inhibitor
2.2 Incyte’s LY3009104, JAK 1, 2 Inhibitor
2.3 Immune Response BioPharma, Inc’s RAVAX RA Vaccine
2.4 Discovery of a new pathway?
2.5 The future of RA Therapy
3 Appendix
3.1 Methodology
3.1.1 Coverage
3.1.2 Secondary Research
3.1.3 Primary Research
3.1.4 Expert Panel Validation
3.2 Contact Us
3.3 Disclaimer

Customers who bought this item also bought

• Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
• Rheumatoid Arthritis (Event Driven)
• Rheumatoid Arthritis Therapeutics - Global Strategic Business Report
• Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 - Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion
• Global Rheumatoid Arthritis Drug Pipeline Capsule - 2012 Update
• The Rheumatoid Arthritis Market - Competitive Landscape and Clinical Stage Analysis
• Rheumatoid Arthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
• Rheumatology Thought Leader Panel #36 2012-08 Lupus / Rheumatoid Arthritis
• Rheumatology Therapeutics Market to 2018 - Increasing Uptake of Benlysta, Uloric, Krystexxa, and the Launch of Oral Tofacitinib to Spur Growth
• Product Profiles: Disease Modification in Rheumatoid Arthritis - Game-changing therapy close to market